Fourth-quarter net income fell 87% against a tough year-earlier comparison, though revenue rose thanks largely to strong sales growth of Shire’s attention-deficit-hyperactivity disorder drug Vyvanse.
from WSJ.com: US Business http://ift.tt/1Q9gJHQ
via IFTTT
No comments:
Post a Comment